Piciu Andra, Larg Maria-Iulia, Piciu Doina
Department of Medical Oncology Iuliu Hațieganu, University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Endocrine Tumors and Nuclear Medicine, Institute of Oncology "Prof.dr.Ion Chiricuță" 400015 Cluj-Napoca, Romania.
J Pers Med. 2020 Jun 19;10(2):52. doi: 10.3390/jpm10020052.
In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation.
在甲状腺肿瘤病理学中，BRAF V600E突变被证明与甲状腺乳头状癌及其亚型的肿瘤发生有关。本研究的目的是评估一组20例接受根治性治疗（全甲状腺切除术和放射性碘治疗）的甲状腺乳头状癌患者在初始治疗6个月后，BRAF V600E癌基因突变与18F-氟脱氧葡萄糖（F18-FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）评估中的病理标准化摄取值（SUV）之间的相关性，这些患者存在亚临床持续性疾病。我们分析了SUV值与BRAF突变的存在以及其他预后因素之间的相关性，这些预后因素包括分期、年龄、特定肿瘤标志物（甲状腺球蛋白和抗甲状腺球蛋白）、甲状腺外扩展、转移性淋巴结或远处转移的存在。BRAF+（阳性）患者的SUV值高于阴性患者，但无统计学意义，因此，SUV值不能作为基因突变存在的可预测因素。在BRAF+亚组中，SUV值与术后阳性切缘之间存在统计学显著相关性，在PET/CT评估中显示出较高的SUV值。未观察到甲状腺乳头状癌所涉及的上述预后因素与BRAF V600E突变之间存在相关性。
